Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity (e.g. doxorubicin), biologic therapy, or immunotherapy within  days prior to enrollment and/or daily or weekly chemotherapy (e.g. sunitinib, sorafenib and pazopanib) without the potential for delayed toxicity within  days prior to enrollment
Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within  days prior to study day , or daily or weekly chemotherapy without the potential for delayed toxicity within  days prior to study day 
Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within  days prior to study enrollment and/or daily or weekly chemotherapy without the potential for delayed toxicity within  days prior to study enrollment
Has had any major surgery, extensive radiotherapy, or anti-cancer therapy (e.g., chemotherapy with delayed toxicity, biologic therapy, or immunotherapy) within  days prior to enrolment and/or daily or weekly chemotherapy without the potential for delayed toxicity within  days prior to enrolment. Prolonged immobilization must have resolved prior to enrolment.
Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within  days prior to enrollment and/or daily or weekly chemotherapy without the potential for delayed toxicity within  days prior to enrollment
Any major surgery, extensive radiotherapy (>  days of treatment), chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within  days prior to first dose of study treatment and/or daily or weekly chemotherapy without the potential for delayed toxicity within  days prior to first dose of study treatment
Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within  days of enrollment and/or daily or weekly chemotherapy without the potential for delayed toxicity within  days of enrollment
Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within  days prior to randomization and/or daily or weekly chemotherapy without the potential for delayed toxicity within  days prior to randomization
All patients must have completed any prior chemotherapy, targeted therapy and major surgery, >=  days before study entry; for daily or weekly chemotherapy without the potential for delayed toxicity, a washout period of  days may be acceptable, and questions related to this can be discussed with study principal investigator
Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within  days prior to enrollment and/or daily or weekly chemotherapy with the potential for delayed toxicity within  days prior to enrollment
Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within  days prior to randomization and/or daily or weekly chemotherapy or other approved anti-myeloma therapy without the potential for delayed toxicity within  days prior to registration
Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within  days prior to study registration, and/or daily or weekly chemotherapy without the potential for delayed toxicity within  days prior to registration
Prior treatment with: BRAF and/or MEK inhibitor(s); anti-cancer therapy (e.g., chemotherapy with delayed toxicity, immunotherapy, biologic therapy or chemoradiation) within  days or prior nitrosourea or mitomycin C containing therapy within  days prior to enrollment and/or prior daily or weekly chemotherapy or biologic therapy without the potential for delayed toxicity within  days prior to enrolment or prior nvestigational drug(s) within  days or  half-lives, whichever is longer, prior to enrollment
Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within  days prior to randomization; daily or weekly chemotherapy (with the exception of hydroxyurea) without the potential for delayed toxicity within  days prior to randomization unless there is evidence of rapidly progressive disease
Any major surgery or extensive radiotherapy (except that which is required for definitive treatment of primary uveal melanoma), chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within  days prior to initiation of study therapy
Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within  days prior to Study Day  (Parts  and ) or randomization (Part ), or daily or weekly chemotherapy without the potential for delayed toxicity within  days prior to Study Day  (Parts  and ) or randomization (Part ).
Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within  days prior to randomization and/or daily or weekly chemotherapy without the potential for delayed toxicity within  days prior to randomization
Prior treatment with: anti-cancer therapy (e.g., chemotherapy with delayed toxicity, immunotherapy, biologic therapy or chemoradiation) within  days (or within  days if prior nitrosourea or mitomycin C containing therapy) prior to enrollment and/or daily or weekly chemotherapy without the potential for delayed toxicity within  days prior to enrolment. Subjects may remain on luteinizing hormone releasing hormone (LHRH) agonists (i.e., leuprolide, goserelin, triptorelin or histrelin). Subjects must have prior enzalutamide treatment; Any PIK, AKT or mammalian target of rapamycin (mTOR) inhibitors; Investigational drug(s) within  days or  half-lives, whichever is longer, prior to enrollment
Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy must not be given within  days prior to study enrollment; for daily or weekly chemotherapy without the potential for delayed toxicity, a washout period of  days prior to enrollment may be acceptable, and questions related to this can be discussed with study principal investigator
Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within  days prior to enrollment
Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within  days of enrollment and/or daily or weekly chemotherapy without the potential for delayed toxicity within  days of enrollment